THOMAS ALEXANDER WALDMANN, M.D.
Osteopathic Medicine at Rickover Rd, Silver Spring, MD
License number
Maryland D0008819
Category
Osteopathic Medicine
Type
Allergy & Immunology
Address
Address
3910 Rickover Rd, Silver Spring, MD 20902
Phone
(301) 946-6253
(301) 496-9956 (Fax)
(301) 496-9956 (Fax)
Personal information
See more information about THOMAS ALEXANDER WALDMANN at radaris.comName
Address
Phone
3910 Rickover Rd, Wheaton, MD 20902
3910 Rickover Rd, Wheaton, MD 20902
Professional information
Method For Treating Malignancy And Autoimmune Disorders In Humans Using Tac Antibodies
US Patent:
7094404, Aug 22, 2006
Filed:
Jun 7, 1995
Appl. No.:
08/478748
Inventors:
Thomas A. Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/395
US Classification:
4241541, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241531, 4241551, 4241561, 4241731, 4241741, 4241781, 4241811, 4241831, 424 149
Abstract:
The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.
Methods Of Preventing Or Treating T Cell Malignancies By Administering Cd2 Antagonists
US Patent:
2004026, Dec 30, 2004
Filed:
Sep 5, 2003
Appl. No.:
10/657006
Inventors:
Christine Dingivan - Gaithersburg MD, US
Thomas Waldmann - Silver Spring MD, US
Zhuo Zhang - Clarksburg MD, US
Thomas Waldmann - Silver Spring MD, US
Zhuo Zhang - Clarksburg MD, US
International Classification:
A61K039/395
US Classification:
424/155100
Abstract:
The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof
Method For Treating Malignancy And Autoimmune Disorders In Humans
US Patent:
2005020, Sep 22, 2005
Filed:
Dec 6, 2004
Appl. No.:
11/005575
Inventors:
Thomas Waldmann - Silver Spring MD, US
Assignee:
and Human Services - Rockville MD
International Classification:
A61K051/00
US Classification:
424001490
Abstract:
The present invention relates to a method for treating malignancy and autoimmune disorders and for preventing allograft rejection. Conjugated or unconjugated monoclonal anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.
Recombinant Vaccine Viruses Expressing Il-15 And Methods Of Using The Same
US Patent:
2006014, Jul 6, 2006
Filed:
Dec 15, 2003
Appl. No.:
10/538974
Inventors:
Thomas Waldmann - Silver Spring MD, US
Jay Berzofsky - Bethesda MD, US
Jay Berzofsky - Bethesda MD, US
Assignee:
GOVERNMENT of the US, as represented by the Secretary , Department of Health and Human Service - Rockville MD
International Classification:
A61K 48/00, C12N 7/00, C12N 15/867
US Classification:
424093200, 435456000, 435235100
Abstract:
The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.
Method Of Treating Autoimmune Diseases With Interferon-Beta And Il-2R Antagonist
US Patent:
7575742, Aug 18, 2009
Filed:
Nov 27, 2002
Appl. No.:
10/519311
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21, A61K 39/395, C07K 14/00, C07K 16/00
US Classification:
424 854, 4241431, 530351, 53038822
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Method Of Treating Multiple Sclerosis With Interferon-Beta And An Il-2R Antagonist
US Patent:
8298525, Oct 30, 2012
Filed:
Mar 10, 2009
Appl. No.:
12/401543
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21, A61K 39/395, A61K 38/20, C07K 14/55, C07K 16/28
US Classification:
424 854, 4241431, 530351, 5303882
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Constructs Encoding Recombinant Antibody-Toxin Fusion Proteins
US Patent:
6051405, Apr 18, 2000
Filed:
Apr 8, 1992
Appl. No.:
7/865722
Inventors:
David FitzGerald - Silver Spring MD
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L Queen - Palo Alto CA
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L Queen - Palo Alto CA
Assignee:
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Protein Design Labs, Inc. - Fremont CA
Department of Health and Human Services - Washington DC
Protein Design Labs, Inc. - Fremont CA
International Classification:
C07K 1646
US Classification:
435 697
Abstract:
The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.
Method Of Treating Multiple Sclerosis With Interferon-Beta And An Il-2R Antagonist
US Patent:
8636997, Jan 28, 2014
Filed:
Sep 12, 2012
Appl. No.:
13/612763
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21, A61K 39/395, C07K 14/565, C07K 16/28
US Classification:
424 856, 4241441, 530351, 53038822
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Interleukin 2 Receptor And Applications Thereof
US Patent:
5833983, Nov 10, 1998
Filed:
Jun 5, 1995
Appl. No.:
8/463491
Inventors:
Thomas A. Waldmann - Silver Spring MD
Warren J. Leonard - Bethesda MD
Warren J. Leonard - Bethesda MD
Assignee:
The United States of America as represented by the Secretary of Dept. of
Health and Human Services - Washington DC
Health and Human Services - Washington DC
International Classification:
C07K 1628, C07K 1646, A61K 39395
US Classification:
4241301
Abstract:
The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W. sub. 1 and IL2W. sub. 2 have also been described.
Recombinant Antibody-Toxin Fusion Protein
US Patent:
5696237, Dec 9, 1997
Filed:
Jun 5, 1995
Appl. No.:
8/463163
Inventors:
David FitzGerald - Silver Spring MD
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L. Queen - Palo Alto CA
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L. Queen - Palo Alto CA
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
C07K 1646
US Classification:
5303873
Abstract:
The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.